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Endothelial cells play essential roles in maintenance
of vascular integrity, angiogenesis, and wound
repair. We show that an endothelial cell-restricted
microRNA (miR-126) mediates developmental angio-
genesis in vivo. Targeted deletion of miR-126 in mice
causes leaky vessels, hemorrhaging, and partial em-
bryonic lethality, due to a loss of vascular integrity
and defects in endothelial cell proliferation, migra-
tion, and angiogenesis. The subset ofmutant animals
that survives displays defective cardiac neovascula-
rization following myocardial infarction. The vascular
abnormalities of miR-126 mutant mice resemble the
consequences of diminished signaling by angiogenic
growth factors, such as VEGF and FGF. Accordingly,
miR-126 enhances the proangiogenic actions of
VEGF and FGF and promotes blood vessel formation
by repressing the expression of Spred-1, an intracel-
lular inhibitor of angiogenic signaling. These findings
have important therapeutic implications for a variety
of disorders involving abnormal angiogenesis and
vascular leakage.
INTRODUCTION
Endothelial cells (ECs) line the internal surfaces of vascular struc-
tures and play essential roles in vascular development, function,
and disease (Carmeliet, 2003). During blood vessel formation,
known as vasculogenesis, ECs proliferate, migrate, and associ-
ate to form a primitive vascular labyrinth that serves as a scaffold
for recruitment of smooth muscle cells. Subsequent sprouting of
vessels, through angiogenesis, allows for further expansion of
the vascular system and tissue vascularization.
Numerous peptide growth factors promote angiogenesis by
enhancing EC migration, proliferation, survival, and cell-cell in-
teractions. VEGF and FGF, the most potent angiogenic growth
factors, are required for neoangiogenesis during embryogenesis
and adulthood (Cross and Claesson-Welsh, 2001). Binding of
these factors to their cell surface receptors activates the MAP ki-
nase pathway, which promotes angiogenic growth and matura-
tion. Conversely, inhibition of MAP kinase signaling diminishesDevelopangiogenesis (Eliceiri et al., 1998; Giroux et al., 1999; Hood
et al., 2002), and has been advanced as an antiangiogenic
therapy (Hood et al., 2002; Panka et al., 2006).
Recent studies have revealed important roles for microRNAs
in the response of the cardiovascular system to injury and stress
(Latronico et al., 2007; van Rooij and Olson, 2007). miRNAs rep-
resent a class of 22 nucleotide noncoding RNAs that regulate
gene expression by targeting mRNAs for cleavage or transla-
tional repression (Bartel, 2004). More than 500 miRNAs have
been identified in humans and other eukaryotic species, with
about a third encoded by introns of protein coding genes.
miRNAs are initially transcribed as large pri-miRNAs that are pro-
cessed through sequential steps to give rise to a heteroduplex
RNA. The miRNA strand of the heteroduplex becomes incorpo-
rated into the RNA-induced silencing complex (RISC), where it is
enabled to target specific mRNAs through complementary se-
quences in 30 untranslated regions (He and Hannon, 2004). The
opposite strand of the heteroduplex, known as the star (*) strand,
is generally degraded.
Here we show that an endothelial cell-specific miRNA,
miR-126, modulates angiogenesis in vivo. Targeted deletion of
miR-126 in mice results in vascular leakage, hemorrhaging,
and embryonic lethality in a subset of mutant mice. These vascu-
lar abnormalities can be attributed to diminished angiogenic
growth factor signaling, resulting in reduced EC growth, sprout-
ing, and adhesion. The subset of mutant animals that survives is
prone to cardiac rupture and lethality following myocardial in-
farction with defective vascularization of the infarct. The proan-
giogenic actions of miR-126 correlate with its repression of
Spred-1, a negative regulator of MAP kinase signaling. Thus, in
the absence ofmiR-126, increased expression of Spred-1 dimin-
ishes the transmission of intracellular angiogenic signals by
VEGF and FGF.We conclude thatmiR-126 functions as an endo-
thelial cell-specific regulator of angiogenic signaling.
RESULTS
Endothelial-Specific Expression of miR-126
In light of recent studies implicating miRNAs in cardiovascular
development and disease, we searched publicly available data-
bases for miRNAs that appeared to be restricted to cardiovascu-
lar tissues. Among several such miRNAs, miR-126 appeared en-
riched in tissues with a high vascular component, such as heart
and lung (Lagos-Quintana et al., 2002). A survey of miRNAmental Cell 15, 261–271, August 12, 2008 ª2008 Elsevier Inc. 261
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specific for the vascular system (Wienholds et al., 2005).
Northern blot analysis showed miR-126 to be expressed in
a broad range of tissues, with highest expression in lung and
heart (Figure 1A) consistent with prior studies (Harris et al.,
2008; Lagos-Quintana et al., 2002; Musiyenko et al., 2008).
miR-126* was detectable at only trace levels of expression
(data not shown). A survey of cell lines revealed miR-126 to be
expressed in primary human umbilical vein ECs (HUVECs) and
in numerous EC cell lines, including the MS1, HAEC, and
EOMA cell lines, but not in SV40 transformed ECs (SVECs) or
nonendothelial cell types (Figure 1A).
miR-126 (also referred to as miR-126-3p) and miR-126* (miR-
126-5p) are conserved from Fugu to Homo sapiens (http://
microrna.sanger.ac.uk/sequences/index.shtml). In mammals
and birds, miR-126 and -126* are encoded by intron 7 of the
EGF-like domain 7 (Egfl7) gene (Figure 1B), which encodes an
EC-specific secreted peptide that has been reported to act as
a chemoattractant and inhibitor of smooth muscle cell migration
(Campagnolo et al., 2005; Fitch et al., 2004; Parker et al., 2004;
Soncin et al., 2003). The expression pattern of miR-126 in tissues
and cell lines parallels that of Egfl7 (Fitch et al., 2004; Soncin
et al., 2003), consistent with the conclusion that the miRNA is
processed from intronic RNA sequence of the pre-Egfl7
mRNA. RT-PCR using RACE-ready cDNAs from human placenta
with primers upstream and downstream of intron 7 of Egfl7
showed that miR-126 was generated from a subset of Egfl7 tran-
scripts in which intron 7 was retained (unpublished data). In situ
Figure 1. Endothelial Cell-Specific Expres-
sion and Gene Structure of miR-126
(A) Expression of miR-126 in different tissues and
cell lines, as detected by northern blot. U6 or 5S
rRNA serves as a loading control. Arrows indicate
the position of pre-miR-126, and arrowheads indi-
cate the mature miR-126. SMC, mouse smooth
muscle cell line; HUVEC, human umbilical vein en-
dothelial cell (EC) line; P19CL6, derivative of P19
embryonic carcinoma cells; C2C12: mouse myo-
blast cell line; MS1, mouse primary islet ECs trans-
formed with SV40 large T antigen; HAEC, human
aortic ECs; SVEC, SV40 transformed mouse
EC line; EOMA, mouse hemangioendothelioma-
derived line.
(B) Structure of the mouse Egfl7 gene. miR-126
(miR-126-3p) and miR-126* (miR-126-5p) are
generated as a stem loop encoded by intron 7.
Evolutionary conservation of miR-126 is shown.
hybridization with mouse embryo sec-
tions using a portion of intron 7 encom-
passing pri-miR-126 as a probe revealed
EC-specific expression of miR-126 from
E7.5 to adulthood (Figure S1, available
online), similar to Egfl7.
EC-Specific Transcription of Egfl7/
miR-126
To further visualize the expression pat-
tern of miR-126 in vivo, we cloned 5.4
kb of genomic DNA immediately 50 of the Egfl7/miR-126 gene
into a lacZ reporter gene and generated transgenic mice. This
DNA fragment was sufficient to direct expression specifically in
ECs throughout embryogenesis and in adult tissues (Figure 2A
and data not shown).
The 5.4 kb DNA fragment contained two regions (Region 1 and
Region 2) of high evolutionary conservation, each of which was
sufficient to direct endothelial-specific expression in vivo
(Figure 2B). Both regions contained conserved consensus se-
quences for binding of Ets transcription factors, which have
been implicated in endothelial-specific transcription (Lelievre
et al., 2001). Ets1 potently transactivated these regulatory re-
gions in transfected COS-7 cells, whereas an Ets1 mutant lack-
ing the DNA binding domain was devoid of activity. Moreover,
mutations in the Ets sites blunted transcriptional activation by
Ets1 (Figure 2C) and abolished expression of the lacZ transgene
in ECs in vivo (data not shown). These findings suggest that Ets
transcription factors are sufficient and necessary for endothelial-
specific transcription of Egfl7/miR-126.
Creation ofmiR-126 Null Mice
To explore the functions of miR-126 in vivo, we deleted the re-
gion of intron 7 of the Egfl7 gene encoding miR-126 and inserted
a neomycin-resistance cassette flanked by loxP sites (Figures 3A
and 3B). Mice heterozygous for the mutant miR-126 allele were
intercrossed to obtain miR-126neo/neo mutants. The presence
of the neomycin cassette in the Egfl7 intron altered the splicing
of surrounding exons, as detected by RT-PCR (Figure 3C, left262 Developmental Cell 15, 261–271, August 12, 2008 ª2008 Elsevier Inc.
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by breedingmiR-126neo/+mice to mice expressing Cre recombi-
nase under control of the CAG promoter normalized the tran-
scription and splicing of Egfl7 (Figure 3C, right panel).
miR-126+/micewere intercrossed toobtainmiR-126/mice.
Neither the mature miR-126 nor the stem loop was expressed in
these animals (Figure 3E). The targeted mutation did not alter
the expression of Egfl7 mRNA (Figure 3C, right panel) or EGFL7
protein (Figure 3D) in tissues from homozygous mutant mice.
Figure 2. Cis-Regulatory Sequences That
Direct Endothelial-Specific Expression of
Egfl7/miR-126
(A) E12.5 transgenic mouse embryo harboring
a lacZ transgene controlled by 5.4 kb 50 flanking
DNA upstream of the Egfl7/miR-126 gene. EC
specific lacZ expression showing (a) whole mount
embryo, and sagittal section in (b) perichondral re-
gion, (c) dermis, (d) brain, and (e) outflow tract.
Scale bar = 50 mm.
(B) Schematic diagrams of genomic regions
upstream of the Egfl7/miR-126 gene tested for
regulation of lacZ in transgenic mice at E12.5.
The fraction of transgenic embryos showing endo-
thelial-specific expression of lacZ is shown. Evolu-
tionary conservation of the Egfl7/miR-126 50 flank-
ing region is shown below. The conserved ETS
binding sites are highlighted in pink and light blue.
(C) Genomic fragment for regulatory region 1(Re-
gion1-Luc) was tested for activation by increasing
amounts of an expression plasmid encoding Ets1
or Ets1 mutant lacking the DNA binding domain
(Ets1mut) in COS-7 cells. A deletion mutation
was introduced into the ETS binding site (Re-
gion1(mut)-Luc). Ets1 activated Region1-Luc but
not Region1(mut)-Luc, while Ets1mut failed to ac-
tivate either construct. Error bars indicate stan-
dard deviation.
Vascular Abnormalities inmiR-126
Mutant Mice
miR-126/ mice were obtained at
a lower than predicted frequency from
miR-126+/ intercrosses (Figure 3F). At
postnatal day 10 (P10), 16% of offspring
obtained from heterozygous intercrosses
were homozygous mutants, versus the
expected 25%. Thus, about 40% of the
miR-126/ mice died embryonically or
perinatally. Analysis of embryos obtained
from timed matings revealedmiR-126/
embryos that were dead or dying with se-
vere systemic edema, multifocal hemor-
rhages, and ruptured blood vessels
throughout embryogenesis (Figures 4A
and 4B). The highest percentage of
embryos with vascular abnormalities
was observed from E13.5 to E15.5
(Figure 3G). However, a failure in growth
of the cranial vessels was observed as
early as E10.5 (Figure 4B), prior to sys-
temic edema, hemorrhage, or overall em-
bryo demise, indicating that the vascular defects represent a pri-
mary effect of miR-126 deletion. Similarly, vascularization of the
retina, which begins at P0 and involves the outward migration of
ECs from the central retinal artery, was severely impaired inmiR-
126/ mice (Figure 4C) in the absence of other morphological
abnormalities.
Histological analysis ofmutant embryos and neonates showed
abnormal thickening of the dermis, a hallmark of edema, with
erythrocytes in the tissue spaces, as well as congestion of redDevelopmental Cell 15, 261–271, August 12, 2008 ª2008 Elsevier Inc. 263
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(A) Strategy to generate miR-126 mutant mice by
homologous recombination. The 96 bp sequence
in Egf17 intron 7, which contains miR-126, was re-
placed with a neomycin resistance cassette (Neo)
flanked by loxP sites. Neo was removed in the
mouse germ line by crossing heterozygous mice
toCAG-Cre transgenicmice. DTA, diphtheria toxin
A.
(B) Southern blot analysis of genomic DNA from
ES cells. DNA was digested with Sca I. Using ei-
ther the 50 probe or 30 probe, the sizes of the
wild-type and mutant (miR-126neo allele) are 11.4
kb and 13.4 kb, respectively. Genotypes are
shown on the top.
(C) Analysis of Egfl7 transcripts in heart (left) or
lung (right) of miR-126neo/neo or miR126/ mice,
as detected by RT-PCR. The Egfl7 gene structure
and the exon numbers are shown on the bottom.
Primers used for RT-PCR were named based on
the exon number in the forward (F) and reverse
(R) direction. Genotypes are shown on the top.
GAPDH was used as a control. Note that Egfl7 ex-
pression is disrupted in the miR-126neo/neo mu-
tants, as shown by RT-PCR with primers 7F and
8R, 6F and 9R, 8F and 10R, and normalized
upon deletion of the neo cassette, as shown by
RT-PCR with the primers indicated.
(D) Detection of EGFL7 and GAPDH protein by
western blot of heart extracts from WT and miR-
126 KO mice.
(E) Detection of miR-126 transcripts by northern
analysis of hearts and lungs. 5S rRNA serves as
a loading control.
(F) Genotypes of offspring from miR-126+/ inter-
crosses. The actual and expected number of
mice for each genotype at the indicated stages is
shown.
(G) Genotypes of embryos from miR-126+/ inter-
crosses. The number of miR-126/ offspring an-
alyzed at each age is shown. Severe vascular de-
fects were defined as edema, hemorrhage, severe
growth retardation, and lethality. Less than 1% of
wild-type or miR-126+/ embryos or neonates
showed vascular abnormalities.blood cells in the liver, which may reflect compensatory erythro-
poiesis caused by hypoxia (Figure 4D). Of the miR-126/ mice
that survived to birth, approximately 12% died by P1 and con-
tainedexcessiveprotein-rich fluid in thepleural spacesof the tho-
racic cavity, an indication of severe edema. The lungs were also
not inflated, possibly secondary to the severe edema (Figure 4D).
Edemaandhemorrhagewerealso observed in the thoracic cavity
outside of the pericardial space in some miR-126/ newborn
mice. These abnormalities suggested a role for miR-126 in main-
tenance of endothelial integrity. Indeed, electron microscopy of
miR-126/ embryos confirmed the lack of endothelial integrity
and revealed extensive rupture of blood vessels and lack of tight
cell-cell interactions (Figure 4E).
Platelet/endothelial cell adhesion molecule (PECAM)-positive
ECs from vascularized tissues of miR-126/ embryos at E15.5
displayed diminished proliferation compared to wild-type ECs,264 Developmental Cell 15, 261–271, August 12, 2008 ª2008 Elsevieas detected by BrdU staining (Figure 4F), whereas proliferation
of non-ECs was not significantly different in wild-type and mu-
tant embryos (data not shown). We detected no difference in ap-
optosis between wild-type and mutant ECs at E15.5 by TUNEL
staining (data not shown).
The survivingmiR-126/mice appeared normal to adulthood
and displayed no obvious abnormalities based on histological
analysis of tissues. Male mutant mice were fertile. However, fe-
males were subfertile with reduced litter size (data not shown).
We conclude that miR-126 plays an important role in mainte-
nance of vascular integrity during embryogenesis, but is not
essential for vascular homeostasis after birth.
Defective Angiogenesis ofmiR-126/ ECs
To explore the angiogenic functions ofmiR-126/, we analyzed
sprouting angiogenesis using an ex vivo aortic ring assay. Aorticr Inc.
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miR-126 Regulates AngiogenesisFigure 4. Vascular Abnormalities in miR-126 Null Mice
(A) Wild-type (WT) and miR-126/ (KO) embryos at E15.5. A subset of KO embryos shows systemic edema and hemorrhages as indicated by the arrows.
(B) Lateral views of cranial regions of WT and miR-126 KO embryos at E10.5. Superficial cranial vessels, shown by arrowheads, are apparent in WT embryos, but
are severely deficient in the mutant. The number of vessels in the cranial region indicated by boxes is shown on the right (n = 6).
(C) Vascularization of the retina at P2 as visualized by PECAM staining. The position of the central retinal artery is demarcated by dashed white lines and the
termini of retinal vessels in the mutant by red arrows. Bar = 200 mm. Relative vascular coverage is shown on the right (n = 3).
(D) H&E staining of sagittal sections of the dermis and liver of E15.5 embryos and lung of neonates of the indicated genotypes. Scale bar in the upper and middle
panel equals 200 mm, and scale bar in the bottom panel equals 500 mm. The bracket indicates the thickening of dermis with erythrocytes and inflammatory cells in
the tissue space in the KO embryo. The arrowheads indicate congestion of red blood cells in KO liver compared to the WT liver. The arrows point to the lungs, in
which the alveoli fail to inflate in the KO mice. Asterisks show edema in the thoracic cavity in KO neonates.
(E) Electron microscopy of capillaries in WT and KO embryos at E15.5. The bracket shows the breakdown of vessels in KO embryos. The green arrows point to
tight junctions inWT endothelial cells. The red arrow points to the red blood cells floating outside of the vessels in KO embryos, while the arrow head indicates the
thinning of the endothelial layer in the vessel of KO embryo. EC, endothelial cell; rbc, red blood cell.
(F) Endothelial cell proliferation in E15.5 KO embryos. Significantly less BrdU (red) and PECAM1 (green) double-positive cells were observed in KO compared to
WT embryos. The red arrows point to the PECAM/BrdU double positive cells, while the white arrows point to the PECAM single-positive cells. Nuclei were stained
with DAPI (blue). Error bars indicate standard deviation. The statistics are shown on the bar graph (p = 0.014).rings from 4-week old miR-126/ mice and wild-type litter-
mates were isolated and cultured on matrigel with endothelial
growth medium containing FGF-2 and VEGF and supplemented
with 3% mouse serum. ECs from wild-type mice showed exten-
sive outgrowth between days 4 and 6 of culture, whereas endo-
thelial outgrowth was dramatically impaired in aortic rings ob-
tained from miR-126/ mice (Figure 5A). Staining for PECAM
confirmed the identity of ECs in aortic ring cultures (data not
shown).DevelopWe further analyzed the angiogenic response of ECs in miR-
126/ mice in vivo using a matrigel plug EC invasion assay in
which mice were injected subcutaneously with a matrigel plug
containing the proangiogenic factor FGF-2, or PBS as control.
In response to angiogenic growth factor signaling, ECs typically
migrate into the matrigel plug and assemble into a primitive vas-
cular network, which can be detected by PECAMstaining 1week
later. EC invasion requires angiogenic growth factors and is not
observed in PBS control matrigel plugs. ECs from miR-126/mental Cell 15, 261–271, August 12, 2008 ª2008 Elsevier Inc. 265
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(A) Representative images of cultured aortic rings isolated fromwild-type (WT) andmiR-126/ (KO) mice at days 4–6 are shown. Extensive endothelial outgrowth
can be seen in WT explants, but not in mutants. Relative migratory activity under each condition was quantified as shown in the bar graphs with statistics. Error
bars indicate standard deviation.
(B) Representative images of PECAM1 (green) staining of matrigel plugs implanted into mice of the indicated genotypes are shown. Significantly less angio-
genesis was observed in the matrigel with FGF-2 in KO mice compared to WT mice. No significant angiogenesis was observed in the matrigel plugs lacking
FGF-2 in WT or KO mice. Scale bar = 60 mm.
(C) The extent of angiogenesis in thematrigel plug assaywas quantified by determining PECAM staining area using Image J software. Error bars indicate standard
deviation. p = 0.0008 for KO compared to WT matrigel plugs.
(D) Survival of WT and KO mice following MI. P value equals 0.05 and 0.014 for the survival of KO mice compared to WT for 1 week and 3 week post-MI.
(E) Histological analysis of hearts fromWT and KOmice following MI. Panels a–d show longitudinal sections through the right ventricle (RV) and left ventricle (LV).
Note thrombi in the atria of the mutant heart, indicative of heart failure. Panels e and f show transverse sections stained with Masson’s trichrome to reveal scar
formation. Note the extensive loss of myocardium in the KO mice. Panels g and h show PECAM1 staining in the boxed infarct region from e and f. Note the
deficiency of vasculature in KO mice following MI. The scale bar in a–f equals 1 cm, and the scale bar in g and h equals 40 mm.mice showed a dramatically diminished angiogenic response to
FGF-2 compared to controls (Figures 5B and 5C).
Reduced Survival ofmiR-126/ Mice Following
Myocardial Infarction
The diminished angiogenic response of miR-126/ ECs
revealed in the matrigel EC invasion assay suggested that miR-
126 might play an important role in neoangiogenesis of adult
tissues, as occurs in response to injury. Neoangiogenesis is es-
sential for cardiac repair following myocardial infarction (MI),
when collateral vessels form at the site of the infarct to maintain
blood flow to ischemic cardiac tissue (Kutryk and Stewart, 2003).
Myocardial vascularization following MI requires signaling by
VEGF and FGF (Scheinowitz et al., 1997; Syed et al., 2004).
We therefore compared the response of wild-type and miR-
126 null mice to MI following surgical ligation of the left coronary266 Developmental Cell 15, 261–271, August 12, 2008 ª2008 Elsevieartery. MI in wild-typemice typically results in an infarct, followed
by the formation of a scar. Under the surgical conditions for these
experiments, 70%of wild-typemice survived for at least 3weeks
followingMI (Figure 5D). In contrast, half ofmiR-126/mice died
by 1 week post-MI, and nearly all died by 3 weeks (Figure 5D).
Unoperated hearts from wild-type and miR-126 mutant mice
were indistinguishable histologically (Figure 5E, a and b). One
week after MI, mutant mice showed ventricular dilatation com-
pared to wild-type hearts and commonly developed atrial
thrombi (Figure 5E, c and d), indicative of heart failure. By 3
weeks post-MI, histological analysis showed more extensive fi-
brosis and loss of functional myocardium in miR-126 mutants
compared to wild-type controls (Figure 5E, e and f). Many miR-
126 mutant animals that died during this period also displayed
ventricular rupture, a known consequence of inadequate myo-
cardium that can result from deficient blood flow (data notr Inc.
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type mice following MI.
PECAM staining revealed extensive vascularization of the in-
jured myocardium in wild-type mice 3 weeks following MI. In
contrast, there was a relative paucity of new vessels in the mu-
tants, and those vessels that were observed appeared truncated
and fragmentary (Figure 5E). Thus, miR-126 appears to be im-
portant for normal neovascularization following MI.
Modulation of Angiogenic Signaling by miR-126
The vascular defects inmiR-126/ embryos, combined with the
impaired angiogenic activity of mutant ECs, suggested that miR-
126 was essential for normal responsiveness of ECs to angio-
genic growth factors. To further test this possibility, we infected
HUVECs with a miR-126 expressing adenovirus (Ad-miR-126)
and examined MAP kinase activation by FGF-2, as detected
by phosphorylation of ERK1/2. As shown in Figure 6A, activation
of ERK1/2 phosphorylation by FGF-2 was enhanced approxi-
mately 2-fold by Ad-miR-126 compared to an Ad-lacZ control.
Conversely, knockdown of miR-126 expression with a 20-0-
methyl-miR-126 antisense oligonucleotide diminished ERK
phosphorylation in response to VEGF, compared to a control
oligonucleotide (Figure 6B). These findings suggested that miR-
126 augments MAP kinase pathway activation by FGF and
VEGF.
Inhibition of Spred-1 Expression by miR-126
To identify potential mRNA targets of miR-126 that might con-
tribute to the endothelial abnormalities of miR-126 mutant
mice, we compared the gene expression profiles by microarray
analysis of ECs isolated from adult kidneys of wild-type and
miR-126 null mice. SincemostmiRNAs promote the degradation
of their target mRNAs (Jackson and Standart, 2007), we focused
on mRNAs that were upregulated inmiR-126/ ECs (Table S1).
NumerousmRNAs involved in angiogenesis, cell adhesion, inflam-
matory/cytokine signaling, and cell cycle control were upreg-
ulated in miR-126/ EC cells. Among this group of transcripts,
we identified three mRNAs that were also predicted by various
miRNA target prediction programs to be evolutionarily con-
served targets of miR-126 (Table S2): Sprouty-related protein-1
(Spred-1), VCAM-1, and integrin a-6. Indeed, VCAM-1 mRNA
was recently shown to be a target for repression by miR-126
in vitro (Harris et al., 2008).
Intriguingly, Spred-1 has been shown to function as a negative
regulator of the Ras/MAP kinase pathway (Wakioka et al., 2001).
Given the ability of miR-126 to enhance MAP kinase signaling in
response to VEGF and FGF, and the diminished angiogenic
growth factor signaling in the absence of miR-126, Spred-1
seemed a likely mediator of the angiogenic actions of miR-126.
The predicted energy of the miR-126/Spred-1 interaction is
17.9 kcal/mol. Most importantly, the ‘‘seed’’ region (nucleo-
tides 1–7) of miR-126 is completely complementary to the
sequence of the Spred-1 30UTR, and the complementary
sequences of miR-126 and the Spred-1 30 UTR are conserved
from amphibians to mammals (Figure 6C). Consistent with the
conclusion that Spred-1 mRNA is a target for repression by
miR-126, Spred-1 protein expression was increased in yolk
sac from miR-126/ mice compared to wild-type littermates
(Figure 6D). In contrast, CT10 regulator of kinase (CRK), whichDevelois predicted by several miRNA target prediction programs to
be a miR-126 target, was unchanged, as was GAPDH, as
a control.
When the Spred-1 30 UTR was fused to a luciferase reporter
and tested for repression by miR-126 in transfected cells, miR-
126 strongly repressed expression of the Spred-1 30 UTR lucifer-
ase reporter (Figure 6E). Mutation of six nucleotides in the miR-
126 ‘‘seed’’ region (miR-126 m) or its complementary sequence
in the Spred-1 30 UTR (Spred-1 m UTR) relieved the repressive
effect of miR-126 (Figure 6E). Infection of HUVEC cells with an
adenovirus expressing miR-126 also repressed expression of
Spred-1 mRNA by about 2-fold (Figure 6F). Conversely, a miR-
126 antisense RNA elevated the expression of Spred-1 mRNA
in HAEC cells (Figure 6F). The efficiency of miR-126 overexpres-
sion or knockdown was monitored by northern blot analysis with
miR-126 probe (data not shown).
To establish whether miR-126 is necessary to repress Spred-1
expression, ECs were isolated from the kidneys of miR-126/
and wild-type adult mice. The identity of ECs was monitored
by the uptake of DiI-labeled acetylated low density lipoprotein
(DiI-Ac-LDL) and staining with an antibody against von Wille-
brand factor (data not shown). As expected, Spred-1 mRNA
was significantly upregulated in miR-126/ ECs compared to
wild-type ECs (Figure 6G), confirming the microarray results.
Further support for the involvement of Spred-1 in inhibiting
miR-126-modulated EC migration and angiogenesis, was pro-
vided by the aortic ring assay in which retrovirus-mediated over-
expression of Spred-1 diminished EC outgrowth (Figure 6H),
whereas knockdown of Spred-1 expression with a small interfer-
ing RNA enhanced endothelial outgrowth in explants from miR-
126/ mice (Figure 6H). Finally, in a scratch-wound assay
in vitro, miR-126 antisense RNA dramatically impaired HUVEC
migration, whereas Spred-1 siRNA restored migratory activity
to cells expressing miR-126 antisense RNA (Figure 6I). These re-
sults support the conclusion that miR-126 augments angiogenic
signaling by diminishing the inhibitory influence of Spred-1 on
the MAP kinase pathway.
DISCUSSION
The results of this study reveal an essential role for miR-126 in
angiogenesis and maintenance of vascular integrity in vivo. The
actions of miR-126 appear to reflect, at least in part, its potenti-
ation of MAP kinase signaling downstream of VEGF and FGF,
which act as potent inducers of angiogenesis (Figure 7).
Spred-1, an intracellular inhibitor of the Ras/MAP kinase path-
way, serves as a target for repression by miR-126. Thus, in the
absence of miR-126, Spred-1 expression is elevated, resulting
in repression of angiogenic signaling. Conversely, miR-126 over-
expression relieves the repressive influence of Spred-1 on the
signaling pathways activated by VEGF and FGF, favoring angio-
genesis. Consistent with these findings, overexpression of
Spred-1 in ECs impairs angiogenesis and cell migration, mimick-
ing the miR-126 loss-of-function phenotype, whereas knock-
down of Spred-1 expression enhances angiogenesis and res-
cues the miR-126 loss-of-function phenotype in cultured ECs.
It is intriguing that only a subset of miR-126/ embryos suc-
cumbs to embryonic lethality from vascular rupture, whereas
others survive to adulthood. We propose that miR-126pmental Cell 15, 261–271, August 12, 2008 ª2008 Elsevier Inc. 267
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(A) miR-126 enhances FGF-dependent phosphorylation of ERK1/2. HUVEC cells were infected with adenovirus expressing lacZ or miR-126, and treated with
FGF-2 (10 ng/ml) for the indicated periods of time. Cell lysates were immunoblotted with the indicated antibodies to determine the level of phosphorylated
and total ERK1/2. Ad-miR-126 enhanced FGF-2 dependent phosphorylation of ERK1/2.
(B) Knockdown of miR-126 diminishes VEGF-dependent phosphorylation of ERK1/2. HAEC cells were transfected with 20-O-methyl-miR-126 antisense oligonu-
cleotide or control oligonucleotide, and treated with VEGF (10 ng/ml) for 10 min. Cell lysates were immunoblotted with the indicated antibodies to determine the
level of phosphorylated and total ERK1/2. GAPDH was used as a loading control.
(C) Sequence alignment of miR-126 with Spred-1 30 untranslated regions (UTRs) from different species.
(D) Detection of Spred-1, CRK, and GAPDH protein by western Blot of yolk sac extracts of E15.5 WT and miR-126 KO embryos.
(E) miR-126 targets the Spred-1 30 UTR. The 30 UTR of Spred-1 mRNA, and the Spred-1 m 30 UTR with mutations engineered in the region complementary to the
miR-126 seed region (GGTACGA to TTGGAAG), was inserted into the pMIR-REPORT vector (Ambion). ThemiR-126mutant (miR-126m) construct consists of the
miR-126-3p sequence CGTACCmutated to GCATGG, and the correspondingmiR-126-5p sequenceGGTACGmutated toCCATGC. Transfection of COS-7 cells
was performed using the indicated combination of plasmids. CMV-bGAL was used as an internal control for transfection efficiency. Error bars indicate standard
deviation. P values are shown; ns, not significant.
(F) Relative Spred-1mRNA expression level uponmiR-126 overexpression or knockdown. HUVEC or HAEC cells were subjected to the indicated treatments, and
the level of Spred-1 mRNA was determined by real-time PCR. GAPDH served as a control. Error bars indicate standard deviation. P values are shown.
(G) Upregulation of Spred-1 mRNA inmiR-126/ endothelial cells. The level of Spred-1 mRNA was determined by real-time PCR with L7 as control. Error bars
indicate standard deviation. p = 0.01 for KO compared to WT.
(H) Representative images of cultured aortic rings isolated from wild-type (WT) andmiR-126 KO mice at days 5 and 6 are shown. Adenoviral overexpression of
Spred-1 inWT explants impairs endothelial outgrowth, whereas siRNA-mediated knockdown of Spred-1 in explants frommiR-126 KOmice enhances endothelial
outgrowth. Relative migratory activity under each condition was quantified as shown in the bar graphs with statistics. Error bars indicate standard deviation.
(I) Scratch-wound assay of HUVEC cells response to VEGF. Knockdown ofmiR-126 expression with antisense RNA impairs ECmigration, whereas knockdown of
Spred-1with siRNA restoresmigration in the presence ofmiR-126 antisense RNA. The edges of the scratch-wound are shown by red dashed lines. Migrated cells
were quantified as shown in the bar graphs with statistics. Error bars indicate standard deviation.stochastically modulates critical angiogenic signaling events
during a temporal window in embryogenesis, perhaps because
of a specific threshold of angiogenic signaling at this stage. If268 Developmental Cell 15, 261–271, August 12, 2008 ª2008 Elseembryos are able to pass this developmental time point, the
functions of miR-126 may become less critical for maintenance
of the vasculature. The partial embryonic lethality of miR-126vier Inc.
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expression programs, rather than functioning as an ‘‘on-off’’
switch for angiogenesis.
In addition to its requirement in normal vascular development
during embryogenesis, the functions of miR-126 appear to be
important following MI, when injured vessels at the site of the in-
farct initiate neoangiogenesis to restore blood flow to the injured
myocardial wall. Under conditions of stress, as in the heart
following MI, the actions of miR-126 may acquire heightened
importance due to the requirement of angiogenic signaling for
neovascularization. In this regard, VEGF and FGF expression in-
creases in response to myocardial ischemia and is critical for the
development of collateral vessels in the ischemic myocardium
(Semenza, 2003). Cardiac injury, in addition to activating the mi-
gration and proliferation of nearby ECs, results in the homing of
circulating hematopoietic progenitor cells to sites of ischemia
and their contribution to cardiac repair (Kocher et al., 2001; Ta-
kahashi et al., 1999). miR-126 is expressed in hematopoietic
stem cells, and might therefore contribute to the regenerative
functions of this cell population (Garzon et al., 2006; Landgraf
et al., 2007).
Control of Angiogenesis by miR-126
Angiogenic growth factors, such as VEGF and FGF, modulate
EC proliferation, migration, and adhesion by activating the
MAP kinase pathway, which culminates in the nucleus to en-
hance the expression of genes required for angiogenesis and
vascular integrity. The abnormalities associated with miR-126
loss-of-function are similar to the vascular defects resulting
from the inhibition of MAP kinase signaling in ECs (Hayashi
et al., 2004).
Consistent with the conclusion that miR-126 promotes angio-
genesis by dampening the expression of Spred-1, Spred-1 in-
hibits cell motility and Rho-mediated actin reorganization
(Miyoshi et al., 2004), processes important for angiogenesis.
Figure 7. A Model for the Function of miR-126 in Angiogenesis
Binding of VEGF and FGF to their receptors on ECs leads to activation of the
MAP kinase signaling pathway, which culminates in the nucleus to stimulate
the transcription of genes involved in angiogenesis. miR-126 represses the
expression of Spred-1, a negative regulator of Ras/MAP kinase signaling.
Thus, loss of miR-126 function diminishes MAP kinase signaling in response
to VEGF and FGF, whereas gain of miR-126 function enhances angiogenic
signaling.DeveloSpred-1, and other members of the Spred family, function as
membrane-associated suppressors of growth factor-induced
ERK activation and block cell proliferation and migration in re-
sponse to growth factor signaling (Wakioka et al., 2001). The in-
hibitory actions of Spred proteins are mediated by interference
of phosphorylation and activation of Raf, an upstream activator
of the MAP kinase pathway. Among the three Spred proteins,
only Spred-1 contains a predicted target sequence for miR-
126. While our results are consistent with the conclusion that
Spred-1 plays a major role as a mediator of the proangiogenic
actions of miR-126, it is likely that the actions of miR-126 reflect
the combined functions of multiple target proteins that modulate
angiogenesis and vascular integrity.
Biogenesis of miR-126
Based on the coexpression of miR-126 and Egfl7mRNA, as well
as our finding that miR-126 is generated from a retained intron in
a subset of Egfl7 pre-mRNAs (unpublished data), we conclude
that miR-126 originates from the Egfl7 pre-mRNA. In support
of this, Ets binding sites, which are required for endothelial-
specific gene expression, are not present in intron 7 of the
Egfl7 gene. While our data suggest that intron inclusion is
a mechanism for miR-126 biogenesis, whether it is a mechanism
for other intronic miRNAs is still unknown.
Recently, Egfl7 knockout mice were reported to display vas-
cular abnormalities remarkably similar to those of miR-126 null
mice (Schmidt et al., 2007). The deletion mutation in those
mice was reported to result in the absence of an Egfl7 transcript,
suggesting thatmiR-126 expression is also eliminated. However,
miR-126 expression was not examined. Thus, the possibility that
the phenotype of those mutant mice actually reflects the loss-
of-function of miR-126 warrants consideration.
It is becoming increasingly apparent that the integration of
miRNAs into introns of protein coding genes represents a com-
mon mechanism for coordinating the expression and regulatory
functions of miRNAs with protein coding genes. As another ex-
ample of this form of coregulation, we showed previously that
miR-208, which is encoded by an intron of the a-myosin heavy
chain (MHC) gene, functions within a regulatory network to con-
trol cardiac stress response (van Rooij et al., 2007). Incorporation
of a miRNA into an intron of a tissue-specific gene provides an
efficient mechanism for ensuring the coregulation of the miRNA
with the gene programs it regulates.
Therapeutic Implications
The endothelium playsmyriad roles in cardiovascular homeosta-
sis and remodeling during disease, including the control of
vascular tone and permeability, smooth muscle cell growth
and proliferation, leukocyte adhesion, coagulation, and throm-
bosis. miRNAs have been implicated in regulating EC gene ex-
pression and function in vitro (Kuehbacher et al., 2007; Suarez
et al., 2007), but the functions of miRNAs in EC biology in vivo
have not been explored. The discovery that miR-126 is required
for vascular integrity and angiogenesis, as well as survival post-
MI, suggests that strategies to elevate miR-126 in the ischemic
myocardium could enhance cardiac repair. Conversely, dimin-
ishing miR-126 expression may be efficacious in settings of
pathological vascularization, such as cancer, atherosclerosis,
retinopathy, and stroke. Recently, miR-126 was reported topmental Cell 15, 261–271, August 12, 2008 ª2008 Elsevier Inc. 269
Developmental Cell
miR-126 Regulates Angiogenesisinhibit tumorigenesis and to be downregulated in metastatic
breast tumors, although the specific cell type in which it was
downregulated and the targets of miR-126 that might mediate
these actions were not defined (Tavazoie et al., 2008). We spec-
ulate that miR-126 and other miRNAs will be found to play key
roles in tissue remodeling and diseases.
EXPERIMENTAL PROCEDURES
Generation of miR-126 Mutant Mice
Methods togeneratemiR-126nullmicearedescribed in theSupplementalData.
Surgical Procedure
Mice were subjected to MI by coronary artery ligation as described in the
Supplemental Data. Animal surgical procedures were approved by the UT
Southwestern IACUC.
miRNA Northern Blot
Generation and Analysis of Transgenic Mice
Transgenes were generated by cloning DNA fragments from the Egfl7 50 flank-
ing region into the hsp68 basal promoter upstream of a lacZ reporter gene
(Kothary et al., 1989). These reporter constructs were injected into fertilized
oocytes from B6C3F mice and implanted into pseudopregnant ICR mice.
Embryos were collected and stained for b-galactosidase activity. Transgenic
embryos were identified by PCR analysis with lacZ primer pairs.
Histology, BrdU Labeling, TUNEL Assay, and Immunohistochemistry
Histology was performed as described (Chang et al., 2006). For BrdU labeling,
animals were injected intraperitoneally with 100 ug BrdU/g 4 hr prior to sacri-
fice. For whole-mount immunostaining, embryos or P2 retinas were fixed in
4% paraformaldehyde for 2 hr and processed for staining with PECAM using
standard procedures. For section immunohistochemistry, embryos or mouse
hearts were fixed in 4% paraformadehyde overnight, and processed for cryo-
section and single or double immunostaining using standard procedures.
Apoptosis was determined by the TUNEL assay using an In Situ Cell Death
Detection Kit, TMR red (Roche).
Cell Culture
Mouse EC isolation was performed as described in the Supplemental Data.
HAEC (Clonetics) and HUVEC (ATCC) cells were grown in EC growth medium
(EGM) (Clonetics/Cambrex). For FGF-2 or VEGF treatment, ECs were starved
with EC basal medium (EBM-2) with 0.1% FBS for 24 hr, and then treated with
growth factors for the indicated periods of time. Adenovirus expressing miR-
126 or lacZ was generated and cells were infected as described (Wang et al.,
2008).Retrovirus-expressingSpred-1orGFPwasgeneratedasdescribed (Non-
ami et al., 2004). For miR-126-3p inhibitor transfection, HAEC cells were trans-
fected with 20-O-methyl-miR-126 antisense oligonucleotide (Ambion) and/or
human Spred-1 siRNA pool, or a control oligonucleotide at a concentration of
50 nM using Liptofectamine 2000 (Invitrogen). Forty-eight hours after transfec-
tion, the cellswere starved, treatedwithVEGF-A, and harvested for protein anal-
yses. miR-126 expression was determined by northern blot analysis with miR-
126-3p starfire probe. For aortic ring virus infection, Spred-1 or control GFP
retrovirus was added to the cultured aortic rings. Transfection of the mouse
Spred-1 siRNA pool into miR-126 null aortic rings was performed as described
above. After overnight transfection or infection, the aortic rings were cultured in
freshmedium for 4–6days tomonitor the aortic ring sprouting. The expressionof
Spred-1 was determined by western blot and real-time PCR analysis.
Reporter Assays
The 0.5 kb region 1 enhancer of pEgfl7/miR-126, and the ETS DNA binding site
deletion mutant of the fragment generated by site-directed mutagenesis, was
cloned into the pGL3 vector upstream of an engineered ANF basal promoter.
COS-7 cells in 24-well plates were transfected with 50 ng of reporter plasmids
in the presence or absence of increasing amount of Ets1 or Ets1 DNA-binding
mutant expression plasmid (John et al., 2008).
Spred-1 30 UTR and Spred-1 mutant 30 UTR generated by mutagenesis
were directionally cloned into the pMIR-REPORT vector (Ambion). miR-126270 Developmental Cell 15, 261–271, August 12, 2008 ª2008 Elsevigenomic DNA fragment and miR-126 m DNA fragment were cloned into the
pCMV-Myc vector. Spred-1 or Spred1m UTR construct was then cotrans-
fected with miR-126 or miR-126 m expression plasmid into COS-7 cells.
Reporter assays were performed as described (Chang et al., 2005).
Electron Microscopy
Electron microscopy was performed at Children’s Medical Center of Dallas as
described in the Supplemental Data.
Aortic Ring Assay
Four-well culture dishes (Nunclon Surface, Nunc) were covered with 250 ml of
matrigel (Chemicon) and allowed to gel for 15 min at 37C, 5% CO2. Thoracic
aortas were excised from 4–6 week-old mice. Fibro-adipose tissue was dis-
sected away from the aortas, which were then cut into 1 mm rings, rinsed
with EGM-2 (Cambrex), placed on matrigel coated wells and covered with ad-
ditional Matrigel. The aortic rings were cultured in EGM-2 (Cambrex) plus 3%
mouse serum (Taconic).
In Vivo Matrigel Plug Assay
Growth factor reduced-Matrigel (BD Bioscience) was mixed with heparin
(60 units/ml), and FGF-2 (250 ng/ml, R&D) or PBS as control. Matrigel (0.5
ml) was injected subcutaneously into the ventral area of anesthetized mice.
The animals were euthanized after 7 days, and the Matrigel plugs were care-
fully dissected away from the host tissue, and processed for frozen section
and immunostained for PECAM1.
Scratch-Wound Assay
The scratch-wound assay was performed using HUVEC cells as described
(Wang et al., 2008).
RNA, Western Blot Analysis, and In Situ Hybridization
Standard procedures were used and are described in the Supplemental Data.
Statistics
Statistics was carried out using 2 way t test. P values less than 0.05 were
considered to be significant.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, two
tables, and one figure and are available online at http://www.
developmentalcell.com/cgi/content/full/15/2/261/DC1/.
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